Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Lung Cancer

Free Subscription 02.02.2026 2 Ann Surg Oncol 2 Arch Bronconeumol 3 BMC Cancer 1 Cancer Res 1 Chest 1 Clin Cancer Res 2 Eur J Cardiothorac Surg 1 Int J Cancer 1 J Clin Invest 1 J Thorac Cardiovasc Surg 1 Lung Cancer 1 Mol Cancer Ther 1 Nat Med 1 Oncogene 1 Oncologist

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. LI Z, Shen Y, Dai J, Jin K, et al
   ASO Author Reflections: Risk Factors for Postoperative AE in Patients with Concomitant Lung Cancer and Idiopathic Pulmonary Fibrosis-Insights from Fibrosis Burden and Prophylactic Steroid Use.
   Ann Surg Oncol. 2026 Jan 26. doi: 10.1245/s10434-026-19092.
   PubMed        
   
   
2. YANG MZ, Yang HX
   ASO Author Reflections: Suboptimal Nodal Dissection Could Undermine Long-Term Survival in Patients with Non-Small-Cell Lung Cancer.
   Ann Surg Oncol. 2026 Jan 25. doi: 10.1245/s10434-026-19106.
   PubMed        
   
   

   
   Arch Bronconeumol

3. MOLINA R, Trape J, Garrido A, Salas E, et al
   Clinical Application of Expert Software Based on Six Tumour Biomarkers to Stratify the Risk of Lung Cancer in a Pulmonary Rapid Diagnosis Unit.
   Arch Bronconeumol. 2026 Jan 9:S0300-2896(26)00003.
   PubMed         Abstract available
   
   
4. MAZZONE PJ
   The Future of Lung Cancer Screening.
   Arch Bronconeumol. 2026 Jan 9:S0300-2896(26)00005.
   PubMed        
   
   

   
   BMC Cancer

5. LI Z, Gao X, Wang Q, Zhao Z, et al
   Genome-wide DNA methylation profiling reveals body mass Index-dependent epigenetic signatures associated with lung cancer susceptibility.
   BMC Cancer. 2026 Jan 28. doi: 10.1186/s12885-025-15536.
   PubMed        
   
   
6. BENBRAHIM Z, Siyouri O, Fetohi M, Benchakroun N, et al
   Brief report: immune checkpoint inhibitors use in lung cancer: a real-world outcome study in a middle-income country.
   BMC Cancer. 2026 Jan 26. doi: 10.1186/s12885-025-15008.
   PubMed        
   
   
7. HUANG M, Xiao W, Lin G, Li C, et al
   A contrastive learning method integrating pathological prior information for effective differentiation of histological categories in lung squamous cell carcinoma.
   BMC Cancer. 2025;26:114.
   PubMed         Abstract available
   
   

   
   Cancer Res

8. QI L, Dang G, Ling X, Miao Y, et al
   Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression.
   Cancer Res. 2026 Jan 27. doi: 10.1158/0008-5472.CAN-25-2871.
   PubMed         Abstract available
   
   

   
   Chest

9. MANFUL A, Amanna N, Park SL, Petrick JL, et al
   THE IMPACT OF THE 2023 ACS SCREENING RECOMMENDATIONS ON RACIAL, ETHNIC, AND SEX DISPARITIES IN LUNG CANCER SCREENING ELIGIBILITY.
   Chest. 2026 Jan 22:S0012-3692(26)00122-4. doi: 10.1016/j.chest.2026.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

10. LIU Y, Nashed J, Barone AK, Yuan M, et al
    FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-2287.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

11. XU Y, Wei S, Yang Z, Chen N, et al
    Effect of surgical resection on isolated pleural dissemination in patients with stage IV (M1a) non-small cell lung cancer: Analysis from a cohort-based registry and a population-based database.
    Eur J Cardiothorac Surg. 2026 Jan 25:ezag050. doi: 10.1093.
    PubMed         Abstract available
    
    
12. MONTEIRO DELA VEGA AJ, Terra RM, Leone Lauricella L, Rocha Junior E, et al
    Lymph node upstaging in robotic, video-assisted thoracic surgery, and open lung resections: a matched analysis from the Brazilian Lung Cancer Registry.
    Eur J Cardiothorac Surg. 2026 Jan 25:ezag051. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Int J Cancer

13. WANG A, Wang S, Zhang S, Liu F, et al
    Discovery of biomarkers in the era of radioimmunotherapy against lung cancer: A bench-to-bedside promise.
    Int J Cancer. 2026 Jan 28. doi: 10.1002/ijc.70352.
    PubMed         Abstract available
    
    

    
    J Clin Invest

14. KENT JR, Abbott KL, Nordgren R, Deik A, et al
    Intraoperative arteriovenous patient sampling to assess in situ non-small cell lung cancer metabolism.
    J Clin Invest. 2026 Jan 27:e198821. doi: 10.1172/JCI198821.
    PubMed        
    
    

    
    J Thorac Cardiovasc Surg

15. GHANI A, Seyoum N, Eaton DB Jr, Malone S, et al
    Characterizing Phantom Lymph Node Collection During Curative-Intent Resection of Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2026 Jan 27:S0022-5223(26)00081.
    PubMed         Abstract available
    
    

    
    Lung Cancer

16. HUANG Y, Deng Q, Li J, Wang R, et al
    Proteomic profiling of early-stage non-small cell lung cancer identifies a high-performance protein signature associated with postoperative recurrence.
    Lung Cancer. 2026;213:108907.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

17. SHIELDS MD, Minton KG, Ozakinci H, Zhou T, et al
    ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin.
    Mol Cancer Ther. 2026 Jan 26. doi: 10.1158/1535-7163.MCT-25-0663.
    PubMed         Abstract available
    
    

    
    Nat Med

18. DUTTAGUPTA S, Messaoudene M, Hunter S, Desilets A, et al
    Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.
    Nat Med. 2026 Jan 28. doi: 10.1038/s41591-025-04186.
    PubMed         Abstract available
    
    

    
    Oncogene

19. VAN GENUGTEN JHLT, Fennell DA, Baas P
    BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities.
    Oncogene. 2026;45:593-602.
    PubMed         Abstract available
    
    

    
    Oncologist

20. PASSIGLIA F, Reale ML, Pasello G, Viscardi G, et al
    Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression >/= 50%: real-world data from the Italian ATLAS registry.
    Oncologist. 2026;31:oyaf428.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.